India Plant Master File (PMF) for Overseas Manufacturing Sites

1. Key takeaways

The Indian Plant Master File (PMF) is prepared under Part II, Appendix I of the Fourth Schedule of the Medical Devices Rules, 2017, and describes the overseas manufacturing site and its quality system. Under Rule 34(1), the CDSCO may inspect the overseas manufacturing site of its own motion or through a delegated party, with the inspection fee borne by the applicant, set at USD 6,000.

• The PMF is the site-level counterpart to the device-level DMF, and the two files must tell a consistent story.
• India is one of the few markets that brings overseas factories inside a documented review, not only the product.
• The USD 6,000 inspection fee is a contingent cost, triggered when the CDSCO decides to inspect, not at submission.
• Inspection can occur before or after the licence is granted, so site readiness must persist across the whole licence life.
• Multiple manufacturing sites can be endorsed onto a single import licence, which concentrates both convenience and risk.
• The PMF, the DMF and the ISO 13485 certificate must agree on what the site actually does, or reviewers will ask why they do not.

2. Legal basis

The PMF obligation and the inspection powers surrounding it come from defined provisions of the Medical Devices Rules, 2017, supplemented by the CDSCO’s official FAQ positions. The table below maps each matter to its source.

3. Expert insights

Insight one: India is one of the few markets that brings overseas factories inside a documented review. It does not only review the product; it also reviews “the conditions under which this product was made”. The PMF must therefore describe the site layout, equipment, utilities, cleanrooms where applicable, personnel and training, process validation, environmental controls, calibration and maintenance, complaint handling, CAPA, and internal audits. A PMF that only lists departments and skips the controls will read like a brochure, and reviewers notice the difference quickly. The document earns credibility from specifics: named processes, defined acceptance limits, and evidence that each control is actually operated.

Insight two: USD 6,000 is a fee, and it is also a trigger. The inspection fee is borne by the applicant, but the point at which it appears is not the submission date — it is the moment the CDSCO decides to inspect. Budgets should carry it as a contingent cost, not a fixed one. Companies that treat it as a one-off sunk cost are often caught unprepared when the inspection request arrives mid-project, together with the scheduling and travel burden that an inspection implies.

Insight three: inspection can happen after the licence is issued. Receiving the MD-15 import licence does not mean the site review is over. The enterprise must maintain the state of the site throughout the entire life of the licence. This means the PMF is not a one-time submission document but a living description: when the site changes — a new line, a relocated cleanroom, a new utility system — the file and the reality must be brought back into alignment.

Insight four: multiple sites can be endorsed on one licence. This is both an administrative convenience and a concentration of risk — a problem at any one site on the licence affects the coverage of all products listed under it. The decision between a single endorsed licence and separate licences should be taken deliberately, weighing the cost of additional applications against the blast radius of a site-level issue. Whichever structure is chosen, it should be documented in the regulatory strategy so that future site additions follow a predictable path rather than an improvised one.

4. Practical recommendations

Before preparing a PMF, GRZAN runs a document-level “Fourth Schedule rehearsal” at the factory: each entry of Appendix I is checked against the existing quality system documentation, and any item not covered is listed directly as a corrective action. The purpose of this exercise is not to show the CDSCO, but to close the gaps before the inspection actually arrives. We also recommend aligning the scope of the ISO 13485 certificate with the scope described in the PMF — a mismatch between the two is a common non-conformity, and it is far cheaper to fix on paper before an auditor finds it on the floor.

• Run the Appendix I gap check against current system documentation before drafting the PMF.
• Align the ISO 13485 certificate scope with the PMF site scope explicitly.
• Book the USD 6,000 overseas inspection fee as a contingent budget line with a lead-time assumption.
• Rehearse inspection readiness for the post-licence period, not only for the application phase.
• Keep the PMF under version control so that site changes trigger a documented review of the file.
• Evaluate single-licence endorsement versus separate licences per site before submitting.

5. Verification checklist

• □ The PMF fully covers the entries of Part II, Appendix I of the Fourth Schedule
• □ Items such as cleanrooms, process validation, calibration, CAPA, and internal audits are in place
• □ The ISO 13485 certificate scope matches the scope described in the PMF
• □ The USD 6,000 overseas inspection fee has been listed as a contingent cost
• □ Multi-site projects have evaluated centralised endorsement versus separate licences

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com